Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lurtotecan SCHEMBL29774186 | 1.00 | TOP1 (1.00) | TOP1SLC2A1 | |
| Lurtotecan SCHEMBL19208 | 1.00 | TOP1 (1.00) | TOP1SLC2A1 | |
| Lurtotecan SCHEMBL1649335 | 0.99 | TOP1 (0.98) | TOP1SLC2A1 | |
| Lurtotecan SCHEMBL29379042 | 0.99 | TOP1 (0.98) | TOP1SLC2A1 | |
| Lurtotecan SCHEMBL1649336 | 0.98 | TOP1 (0.97) | TOP1SLC2A1 | |
| SCHEMBL31312371 | 0.95 | TOP1 (1.00) | TOP1SLC2A1 | |
| SCHEMBL21410041 | 0.95 | TOP1 (1.00) | TOP1SLC2A1 | |
| SCHEMBL21450469 | 0.95 | TOP1 (1.00) | TOP1SLC2A1 | |
| SCHEMBL15150090 | 0.93 | TOP1 (0.87) | TOP1SLC2A1 | |
| SCHEMBL17057475 | 0.92 | TOP1 (0.86) | TOP1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230295313-A1 | IL1RAP BINDING PROTEINS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-09-21 | — | — | US | disclosed |
| EP-4242206-A1 | CRYSTALLINE N-{(1-S)-2-AMINO-1-[(3-FLUOROPHENYL)METHYL]ETHYL}-5-CHLORO-4-(4-CHLORO-1-METHYL-1H-PYRAZOL-5-YL)-2-THIOPHENECARBOXAMIDE HYDROCHLORIDE | Novartis AG (CH) | 2023-09-13 | — | — | EP | disclosed |
| US-11649289-B2 | Anti-ICOS and anti-PD-1 antibody combination therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-11649289-B2 | Anti-ICOS and anti-PD-1 antibody combination therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-20230105887-A1 | NOVEL PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20230067202-A1 | Combination Treatments and Uses and Methods Thereof | GLAXOSMITHKLINE IP DEV LTD (GB) | 2023-03-02 | — | — | US | disclosed |
| US-11565994-B2 | Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACS) | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-01-31 | — | — | US | disclosed |
| US-11504333-B2 | Pharmaceutical composition | NOVARTIS AG (CH) | 2022-11-22 | — | — | US | disclosed |
| WO-2007136940-A2 | THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007103754-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007103756-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007103755-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007103760-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007103759-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007103758-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| WO-2007076320-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007058850-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | TOP1 1730/4885SLC2A1 1299/4885 |
| US-20230105887-A1 | NOVEL PHARMACEUTICAL COMPOSITION | DCPS, SRMS, CYP2D6 | TOP1 2797/4885SLC2A1 3647/4885 |
| US-11504333-B2 | Pharmaceutical composition | SRMS, PFAS, DCPS | TOP1 2096/4885SLC2A1 3705/4885 |
| US-11565994-B2 | Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACS) | KDM1B, KDM2A, EHMT2 | TOP1 1096/4885SLC2A1 3223/4885 |
| US-11649289-B2 | Anti-ICOS and anti-PD-1 antibody combination therapy | ICOS, ICOSLG, CD274 | TOP1 1439/4885SLC2A1 4746/4885 |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | TOP1 531/4885SLC2A1 3305/4885 |
| US-20230295313-A1 | IL1RAP BINDING PROTEINS | IL1RN, IL1R1, IL1A | TOP1 4834/4885SLC2A1 4590/4885 |
| US-20230067202-A1 | Combination Treatments and Uses and Methods Thereof | CD274, PDCD1LG2, PDCD1 | TOP1 840/4885SLC2A1 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.